The Opportunity Ahead
Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders.
Küleon exclusively owns all intellectual property rights associated with our proprietary scaffolds and compounds. Küleon is privately funded by its founders and strategic partners. If you are interested in learning more about partnering with us or exploring investment opportunities, we would love to hear from you!